ADMA Biologics/$ADMA
1D1W1MYTD1Y5YMAX
Capital at risk
About ADMA Biologics
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
- Ticker
- $ADMA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 644
- Headquarters
- Ramsey, United States
- Website
- www.admabiologics.com
ADMA Biologics Metrics
BasicAdvanced
$2B
13.01
$0.70
0.77
-
Price and volume
Market cap
$2B
Beta
0.77
52-week high
$20.46
52-week low
$7.21
Average daily volume
2.4M
Financial strength
Current ratio
6.972
Quick ratio
3.62
Long term debt to equity
0.487
Total debt to equity
0.499
Interest coverage (TTM)
24.53%
Profitability
EBITDA (TTM)
224.193
Gross margin (TTM)
64.71%
Net profit margin (TTM)
32.98%
Operating margin (TTM)
42.26%
Effective tax rate (TTM)
21.95%
Revenue per employee (TTM)
$800,000
Management effectiveness
Return on assets (TTM)
21.78%
Return on equity (TTM)
41.90%
Valuation
Price to earnings (TTM)
13.008
Price to revenue (TTM)
4.183
Price to book
5.03
Price to tangible book (TTM)
5.08
Price to free cash flow (TTM)
18.437
Free cash flow yield (TTM)
5.42%
Free cash flow per share (TTM)
0.494
Growth
Revenue change (TTM)
8.04%
Earnings per share change (TTM)
-17.00%
3-year revenue growth (CAGR)
35.02%
10-year revenue growth (CAGR)
50.21%
3-year earnings per share growth (CAGR)
54.21%
10-year earnings per share growth (CAGR)
-9.26%
What the Analysts think about ADMA Biologics
Analyst ratings (Buy, Hold, Sell) for ADMA Biologics stock.
Analyst projections of the future price of ADMA Biologics stock.
Bulls say / Bears say
ASCENIV revenue grew 24% year-over-year to $102.9 million in Q2 2026, driven by increasing physician adoption and higher patient utilization. (Morningstar ) (Last10K )
In May 2026, the FDA approved ASCENIV’s label expansion to include pediatric immune-compromised patients aged two years and older, broadening ADMA’s addressable primary immunodeficiency population. (SEC ) (Pharmacy Times )
The sale of three plasma collection centers in Q1 2026 reduced ADMA’s internal capacity from ten to seven facilities (a 30% cut), increasing reliance on third-party suppliers and introducing potential supply chain vulnerabilities. (SEC ) (GlobeNewswire )
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
ADMA Biologics Financial Performance
Revenues and expenses
ADMA Biologics Earnings Performance
Company profitability
Upcoming events
No upcoming events
ADMA Biologics News
AllArticlesVideos
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)
Newsfile Corp1 week ago
ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Newsfile Corp4 weeks ago
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)
Newsfile Corp4 weeks ago
Funds containing ADMA Biologics
AllUSDEURGBP
Fund name | Fund size | $ADMA weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.21% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.21% |
iShares Healthcare Innovation£DRDR | £1B | 0.21% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.14% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.14% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.